Skip to main content
OpenTrials
Completed

NCT Number: NCT04200625

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epicardial Fat

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Miami

Miami, Florida, 33136, United States

About this study

This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records.

Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes,
  • BMI ≥27 kg/m2,
  • Age ≥ 18 years old

Exclusion criteria

  • Type 1 diabetes
  • Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors
  • History of diabetic ketoacidosis
  • Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2
  • Acute infective diseases, cancer or chemotherapy
  • Use of systemic corticosteroids within the 3 months prior this study
  • Known or suspected allergy to semaglutide or dulaglutide excipients or related products
  • Pregnancy, breastfeeding or the intention of becoming pregnant

Treatment and study plan

Primary outcomes

  1. Epicardial Fat thickness

    Time frame: 12 weeks

    Ultrasound measured Epicardial Fat thickness

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Registry information

Official study title

Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 16, 2019
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.